Module
Managing CRS, Neurotoxicity, and Infection
Description:
Learn practical strategies to recognize, monitor, and manage cytokine release syndrome (CRS), neurotoxicity (ICANS), and infection risk associated with bispecific antibody therapy in multiple myeloma, with an emphasis on patient safety and care coordination.
Learning Objectives:
- Identify the signs, grading, and early management strategies for CRS and ICANS
- Apply appropriate monitoring tools and interventions
Instructor:
Mary Steinbach, DNP, APRN
Publications:
BISPECIFIC ANTIBODY THERAPY: Exploring Efficacy, Safety, and Transition of Care Management
Videos:
Bispecifics in Multiple Myeloma | Myeloma University
Transitions of Care | Myeloma University
For Patients:
Bispecifics: An Example with Elrexfio
Living Well with Myeloma: Infection Prevention and Management
Bispecific Antibodies: Early Side Effects
Bispecific Antibody Infection Management | Myeloma Made Simple